Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) is a clinical-stage biopharmaceutical company that specializes in developing innovative cell and gene therapies aimed at curing certain cancers and rare diseases. The company's core focus is on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with unmet medical needs. Poseida's pipeline includes autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates, initially targeting hematological malignancies and solid tumors.
Poseida boasts best-in-class genome engineering capabilities, utilizing proprietary tools like the piggyBac™ DNA modification system, nextGEN™ CRISPR, XTN™ TALEN, and the footprint-free™ gene editing system. These tools are virus-free and offer surgical precision in gene editing, enabling the development of highly effective therapies.
Recent achievements include significant advancements in the company's lead program, P-BCMA-ALLO1, a novel BCMA-targeted allogeneic CAR-T therapy for treating relapsed/refractory multiple myeloma (RRMM). The FDA recently granted Orphan Drug Designation for P-BCMA-ALLO1, underscoring its potential to meet high unmet medical needs. Poseida is investigating this therapy in collaboration with Roche, with promising preliminary data presented at major scientific conferences.
In addition to its focus on cancer, Poseida is also advancing genetic medicines for rare diseases. The company has highlighted progress in its gene therapy pipeline, especially for conditions like Hereditary Angioedema and Hemophilia A. These programs employ fully non-viral approaches, leveraging Poseida's advanced genetic engineering and delivery platforms.
Poseida has formed strategic collaborations with industry giants like Janssen and Roche, enhancing its capacity to bring innovative therapies to market. The company also recently entered into a research collaboration with Xyphos Biosciences, a subsidiary of Astellas, to develop novel convertibleCAR® programs targeting solid tumors.
Financially, Poseida reported revenues of $28.1 million for Q1 2024, a substantial increase from the previous year, primarily driven by collaborations with Astellas and Roche. With a strong cash position and additional funding from strategic partnerships, Poseida is well-positioned to advance its pipeline and achieve key milestones in 2024 and beyond.
Learn more about Poseida Therapeutics and its groundbreaking work by visiting www.poseida.com and connecting with the company on X and LinkedIn.
Poseida Therapeutics (Nasdaq: PSTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for P-BCMA-ALLO1, their investigational allogeneic CAR-T cell therapy for relapsed/refractory multiple myeloma. This designation, based on positive Phase 1 clinical data, offers benefits like Fast Track and Breakthrough Therapy designations, enabling increased FDA interaction. P-BCMA-ALLO1 has shown promising efficacy, safety, and rapid 'off-the-shelf' access. New clinical data will be presented at the 21st International Myeloma Society Annual Meeting. The therapy has demonstrated responses in refractory patients, including those previously treated with BCMA-targeted therapies. Poseida plans additional clinical updates in the second half of 2024, in coordination with their strategic partner Roche.
Poseida Therapeutics (Nasdaq: PSTX) will present new clinical data from its ongoing Phase 1 study of P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy for relapsed/refractory multiple myeloma, at the 21st International Myeloma Society Annual Meeting. The presentation will take place on September 27, 2024, in Rio de Janeiro. Poseida has also initiated the Phase 1b portion of the clinical trial, triggering a $20 million payment from partner Roche. The company will host a conference call on September 28, 2024, to review the data. P-BCMA-ALLO1 is based on Poseida's unique stem cell memory T cell (TSCM) platform and is being developed in partnership with Roche to address the need for patient-focused, off-the-shelf therapies in multiple myeloma treatment.
Poseida Therapeutics (Nasdaq: PSTX) presented new data at the SOHO Annual Meeting from a case study of a patient with relapsed multiple myeloma treated with P-BCMA-101, their investigational autologous CAR-T therapy. The study demonstrated reactivation of CAR-T cells and a repeat stringent complete response (sCR) over 3 years after initial treatment.
Key highlights:
- First reported instance of a T-cell engager reactivating CAR-T therapy
- Patient achieved sCR and remained in remission for nearly 2 years after initial treatment
- Upon relapse, treatment with talquetamab led to CAR-T cell reactivation and another sCR
- Patient remains in sCR off all therapy for over 9 months
This case study showcases the potential of Poseida's T stem cell memory (TSCM)-rich CAR-T therapies, which are a core element of their next-generation, off-the-shelf allogeneic CAR-T cell therapies.
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two upcoming investor conferences in September 2024. The company will engage in fireside chats at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 10:30am ET and the 2024 Cantor Global Healthcare Conference on September 17 at 1:20pm ET.
These presentations offer investors an opportunity to gain insights into Poseida's progress in developing non-viral treatments for cancer and rare diseases. Live webcasts of both fireside chats will be accessible on Poseida's website, with replays available for approximately 90 days post-presentation.
Poseida Therapeutics (NASDAQ: PSTX) reported Q2 2024 financial results and updates on its cell therapy and genetic medicine programs. Key highlights include:
- Continued progress in Roche CAR-T partnership with $45 million in milestones in H1 2024
- Astellas collaboration momentum with nomination of first allogeneic solid tumor CAR-T program target
- On track for clinical updates across allogeneic CAR-T pipeline in H2 2024
- FDA granted INTERACT meeting for P-FVIII-101 genetic medicine program
- Q2 revenues of $26.0 million, up from $20.0 million in Q2 2023
- Net loss of $31.4 million for Q2 2024
- Cash position of $237.8 million as of June 30, 2024
The company expects its current cash position and near-term milestones to fund operations into H2 2025.
Poseida Therapeutics (Nasdaq: PSTX) will participate in the Stifel 2024 Virtual Cell Therapy Forum on July 9, 2024. The company's CEO, Kristin Yarema, Ph.D., will join a virtual fireside chat at 7:55 am PT / 10:55 am ET. A live webcast and a replay accessible for 90 days will be available on Poseida's website.
Poseida Therapeutics (Nasdaq: PSTX) announced that its virtual 2024 Annual Meeting of Stockholders will be held on June 17, 2024, at 1:00 p.m. PT. Stockholders of record as of April 18, 2024, are eligible to vote. The meeting will be accessible via live webcast, with registration required by June 14, 2024. Stockholders can view and download proxy materials and the 2023 Annual Report at https://www.proxydocs.com/PSTX, and may submit questions and vote prior to the meeting. Poseida encourages early access to the meeting for a smooth check-in process.
Poseida Therapeutics (Nasdaq: PSTX) announced financial results and updates for Q1 2024. Key achievements include a new research collaboration with Astellas, generating $95 million in milestone and upfront payments. Revenues for Q1 2024 were $28.1 million, a significant increase from $10.3 million in Q1 2023. Research and development expenses rose to $42.9 million due to increased allogeneic clinical program activity, while general and administrative expenses dropped to $9.8 million. The net loss decreased to $24.3 million from $38.8 million in Q1 2023. The company's cash position is strengthened at $198.6 million, expected to fund operations into the second half of 2025.
Strategic collaborations with Roche and Astellas have been instrumental, with P-BCMA-ALLO1 showing promising clinical responses and non-human primate data supporting the safety of P-KLKB1-101. Poseida's pipeline focuses on non-viral gene therapies targeting cancer and rare diseases.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) presents promising data on its non-viral genetic medicine programs at the ASGCT 2024 Annual Meeting. Notable advancements include successful liver gene editing for Hereditary Angioedema and Hemophilia A, with a focus on safety and tolerability. The Company's proprietary technologies enable precise tuning of Factor VIII levels and provide a potentially superior treatment profile. Ongoing developments include dose-finding studies, CMC manufacturing, and additional preparations for IND-enabling studies.
Astellas Pharma Inc. and Poseida Therapeutics, Inc. have entered into a research collaboration and license agreement to develop novel allogeneic CAR-T cell therapies in oncology. The partnership will leverage Poseida's proprietary allogeneic CAR-T platform and Xyphos' ACCELTM technology to create innovative convertibleCAR® programs targeting solid tumors. Under the agreement, Xyphos will reimburse Poseida for research costs and be responsible for product development and commercialization. Poseida will receive an upfront payment of US $50 million, with potential milestone and contingency payments totaling up to US $550 million, along with tiered royalties. The collaboration aims to address unmet medical needs in oncology and expand Astellas' portfolio with cutting-edge CAR-T cell therapies.
FAQ
What is the current stock price of Poseida Therapeutics (PSTX)?
What is the market cap of Poseida Therapeutics (PSTX)?
What is Poseida Therapeutics, Inc.?
What are Poseida's core technologies?
What is P-BCMA-ALLO1?
Who are Poseida's strategic partners?
What diseases is Poseida targeting with its gene therapies?
What recent financial achievements has Poseida reported?
What is Poseida's approach to gene editing?
How can I learn more about Poseida Therapeutics?
What is the significance of the Orphan Drug Designation for P-BCMA-ALLO1?
What are Poseida's future plans?
